Identification

Name
Pomalidomide
Accession Number
DB08910
Type
Small Molecule
Groups
Approved
Description

Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.

Structure
Thumb
Synonyms
Not Available
External IDs
CC-4047
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ImnovidCapsule3 mgOralCelgene Europe Limited2013-08-05Not applicableEu
ImnovidCapsule1 mgOralCelgene Europe Limited2013-08-05Not applicableEu
ImnovidCapsule4 mgOralCelgene Europe Limited2013-08-05Not applicableEu
ImnovidCapsule2 mgOralCelgene Europe Limited2013-08-05Not applicableEu
PomalystCapsule1 mgOralCelgene2014-02-24Not applicableCanada
PomalystCapsule1 mg/1OralCelgene2013-02-18Not applicableUs
PomalystCapsule4 mg/1OralCelgene2013-02-18Not applicableUs
PomalystCapsule4 mgOralCelgene2014-02-24Not applicableCanada
PomalystCapsule2 mgOralCelgene2014-02-24Not applicableCanada
PomalystCapsule2 mg/1OralCelgene2013-02-18Not applicableUs
International/Other Brands
Imnovid
Categories
UNII
D2UX06XLB5
CAS number
19171-19-8
Weight
Average: 273.2441
Monoisotopic: 273.074955855
Chemical Formula
C13H11N3O4
InChI Key
UVSMNLNDYGZFPF-UHFFFAOYSA-N
InChI
InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)
IUPAC Name
4-amino-2-(2,6-dioxopiperidin-3-yl)-2,3-dihydro-1H-isoindole-1,3-dione
SMILES
NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O

Pharmacology

Indication

Pomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.

Structured Indications
Pharmacodynamics

Pomalidomide is more potent than thalidomide (100-times) and lenalidomide (10-times).

Mechanism of action

Promalidomide is an immunomodulatory agent with antineoplastic activity. It is shown to inhibit the proliferation and induce apoptosis of various tumour cells. Furthermore, promalidomide enhances T cell and natural killer (NK) cell-mediated immunity and inhibited the production of pro-inflammatory cytokines, like TNF-alpha or IL-6, by monocytes. The primary target of promalidomide is thought to be the protein cereblon. It binds to this target and inhibits ubiquitin ligase activity. It is also a transcriptional inhibitor of COX2.

TargetActionsOrganism
AProtein cereblon
inhibitor
Human
ATumor necrosis factor
inhibitor
Human
AProstaglandin G/H synthase 2
inhibitor
Human
Absorption

Pomalidomide is generally well absorbed. The major circulating component is the parent compound. Tmax, single oral dose = 2 -3 hours. When 4 mg of promalidomide is given to patients with multiple myeloma, the steady-state pharmacokinetic parameters are as follows: AUC(T) = 400 ng.hr/mL; Cmax = 75 ng/mL. Promalidomide accumulates following multiple doses.

Volume of distribution

Mean apparent volume of distribution (Vd/F), steady-state = 62 - 138 L

Protein binding

12-44% protein bound. It is not concentration dependent.

Metabolism

Promalidomide is hepatically metabolized by CYP1A2 and CYP3A4. The metabolites are 26-fold less active than the parent compound. Minor contributions from CYP2C19 and CYP2D6 have been observed in vitro.

Route of elimination

When a single oral dose (2mg) is given to healthy subjects, 73% of the dose was eliminated in urine. 15% of the dose was eliminated in feces. 2% and 8% of the dose eliminated unchanged as pomalidomide in urine and feces, respectively.

Half life

Healthy subjects = 9.4 hours; Multiple myeloma patients = 7.5 hours.

Clearance

Total body clearance = 7-10 L/hour

Toxicity

Most common adverse reactions (≥30%) included fatigue and asthenia, neutropenia, anemia, constipation, nausea, diarrhea, dyspnea, upper-respiratory tract infections, back pain and pyrexia.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Pomalidomide.Experimental
AbirateroneThe serum concentration of Pomalidomide can be increased when it is combined with Abiraterone.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Pomalidomide.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Pomalidomide.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Pomalidomide.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Pomalidomide.Experimental
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Pomalidomide.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Pomalidomide.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Pomalidomide.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Pomalidomide.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Pomalidomide.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Pomalidomide.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Pomalidomide.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Pomalidomide.Approved, Illicit, Investigational
AmiodaroneThe metabolism of Pomalidomide can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Pomalidomide.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Pomalidomide.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Pomalidomide.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Pomalidomide.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Pomalidomide.Experimental
AprepitantThe serum concentration of Pomalidomide can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Pomalidomide.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Pomalidomide.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Pomalidomide.Approved
AtazanavirThe metabolism of Pomalidomide can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Pomalidomide can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Pomalidomide.Investigational, Vet Approved
AzelastinePomalidomide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzithromycinThe metabolism of Pomalidomide can be decreased when combined with Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Pomalidomide.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Pomalidomide.Illicit
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Pomalidomide.Investigational
BenperidolThe risk or severity of adverse effects can be increased when Benperidol is combined with Pomalidomide.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Pomalidomide.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Pomalidomide.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Pomalidomide.Approved, Investigational
BoceprevirThe metabolism of Pomalidomide can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Pomalidomide can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Pomalidomide can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Pomalidomide.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Bromisoval is combined with Pomalidomide.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Bromperidol is combined with Pomalidomide.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Pomalidomide.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Pomalidomide.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Pomalidomide.Approved, Investigational
BuprenorphinePomalidomide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Pomalidomide.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Pomalidomide.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Pomalidomide.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Pomalidomide.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Pomalidomide.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Pomalidomide.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Pomalidomide.Approved, Illicit, Vet Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pomalidomide.Approved
CaffeineThe metabolism of Pomalidomide can be decreased when combined with Caffeine.Approved
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Pomalidomide.Investigational
CarbamazepineThe metabolism of Pomalidomide can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Pomalidomide.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Pomalidomide.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Pomalidomide.Approved
CeritinibThe serum concentration of Pomalidomide can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Pomalidomide.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Pomalidomide.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Pomalidomide.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Pomalidomide.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Pomalidomide.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Pomalidomide.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Pomalidomide.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Pomalidomide.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Pomalidomide.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Pomalidomide.Approved, Vet Approved
CitalopramThe metabolism of Pomalidomide can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Pomalidomide can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Pomalidomide can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Pomalidomide.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Pomalidomide.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Pomalidomide.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Pomalidomide.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Pomalidomide.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Pomalidomide.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Clopenthixol is combined with Pomalidomide.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Pomalidomide.Approved, Illicit
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Pomalidomide.Approved
ClothiapineThe risk or severity of adverse effects can be increased when Clothiapine is combined with Pomalidomide.Experimental
ClotrimazoleThe metabolism of Pomalidomide can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Clozapine.Approved
CobicistatThe metabolism of Pomalidomide can be decreased when combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Pomalidomide.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Pomalidomide.Approved, Illicit
ConivaptanThe serum concentration of Pomalidomide can be increased when it is combined with Conivaptan.Approved, Investigational
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Pomalidomide.Approved
CrizotinibThe metabolism of Pomalidomide can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Pomalidomide.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Pomalidomide.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Pomalidomide.Approved, Investigational
CyclosporineThe metabolism of Pomalidomide can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Pomalidomide.Experimental
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Pomalidomide.Approved
Cyproterone acetateThe serum concentration of Pomalidomide can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Pomalidomide can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Pomalidomide.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Pomalidomide.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Dapoxetine.Investigational
DarunavirThe metabolism of Pomalidomide can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Pomalidomide can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Pomalidomide can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Pomalidomide can be decreased when combined with Delavirdine.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Pomalidomide.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Pomalidomide.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Pomalidomide.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Pomalidomide.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Pomalidomide.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Pomalidomide.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Pomalidomide.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pomalidomide.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Pomalidomide.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Pomalidomide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Pomalidomide.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Pomalidomide.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Pomalidomide.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Diethyl ether is combined with Pomalidomide.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Pomalidomide.Approved, Illicit
DigitoxinDigitoxin may decrease the cardiotoxic activities of Pomalidomide.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Pomalidomide.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Pomalidomide.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Pomalidomide.Approved, Illicit
DihydroergotamineThe metabolism of Pomalidomide can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Pomalidomide.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Pomalidomide.Experimental, Illicit
DiltiazemThe metabolism of Pomalidomide can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Pomalidomide.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Pomalidomide.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Pomalidomide.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Dixyrazine is combined with Pomalidomide.Experimental
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pomalidomide.Approved, Investigational
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Pomalidomide.Vet Approved
DosulepinThe serum concentration of Pomalidomide can be increased when it is combined with Dosulepin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Pomalidomide.Approved
DoxycyclineThe metabolism of Pomalidomide can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Pomalidomide.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.Approved, Illicit
DronedaroneThe metabolism of Pomalidomide can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Pomalidomide.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Pomalidomide.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Pomalidomide.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Pomalidomide.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Pomalidomide.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Eltanolone is combined with Pomalidomide.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Pomalidomide.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Pomalidomide.Approved, Investigational
EnzalutamideThe serum concentration of Pomalidomide can be decreased when it is combined with Enzalutamide.Approved
ErythromycinThe metabolism of Pomalidomide can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Pomalidomide.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Pomalidomide.Approved
EthanolPomalidomide may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pomalidomide.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Pomalidomide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Pomalidomide.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Pomalidomide.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethyl chloride is combined with Pomalidomide.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Pomalidomide.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Pomalidomide.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Pomalidomide.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Pomalidomide.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Pomalidomide.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Pomalidomide.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Pomalidomide.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Pomalidomide.Approved
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Pomalidomide.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Pomalidomide.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Pomalidomide.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Pomalidomide.Approved
FingolimodPomalidomide may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Pomalidomide.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Fluanisone is combined with Pomalidomide.Experimental
FluconazoleThe metabolism of Pomalidomide can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Pomalidomide.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Pomalidomide.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Pomalidomide.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Pomalidomide.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Pomalidomide.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Pomalidomide.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Pomalidomide.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Pomalidomide.Approved
FluvoxamineThe serum concentration of Pomalidomide can be increased when it is combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Pomalidomide can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Pomalidomide can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Pomalidomide can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Pomalidomide.Approved, Illicit, Investigational
Fusidic AcidThe serum concentration of Pomalidomide can be increased when it is combined with Fusidic Acid.Approved
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Pomalidomide.Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Pomalidomide.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Pomalidomide.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Pomalidomide.Approved, Illicit, Investigational
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Pomalidomide.Investigational
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Pomalidomide.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Pomalidomide.Experimental
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Pomalidomide.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Pomalidomide.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Pomalidomide.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Pomalidomide.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Pomalidomide.Approved, Vet Approved
Hepatitis A VaccineThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Pomalidomide.Approved
Hepatitis B Vaccine (Recombinant)The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Pomalidomide.Approved, Withdrawn
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Pomalidomide.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Pomalidomide.Approved
HydrocodonePomalidomide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Pomalidomide.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.Approved
IdelalisibThe serum concentration of Pomalidomide can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Pomalidomide.Approved
ImatinibThe metabolism of Pomalidomide can be decreased when combined with Imatinib.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Pomalidomide.Approved
IndalpineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Pomalidomide can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Indiplon is combined with Pomalidomide.Investigational
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with Pomalidomide.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Pomalidomide.Investigational
IsavuconazoniumThe metabolism of Pomalidomide can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Pomalidomide.Approved, Vet Approved
IsradipineThe metabolism of Pomalidomide can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Pomalidomide can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Pomalidomide can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Pomalidomide.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Pomalidomide.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Pomalidomide.Approved, Investigational
KetoconazoleThe metabolism of Pomalidomide can be decreased when combined with Ketoconazole.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Pomalidomide.Approved, Investigational
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Pomalidomide.Experimental
LeflunomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Leflunomide.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Pomalidomide.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Pomalidomide.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Pomalidomide.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Pomalidomide.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Pomalidomide.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Pomalidomide.Approved
LidocaineThe metabolism of Pomalidomide can be decreased when combined with Lidocaine.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Pomalidomide.Approved
LobeglitazoneThe metabolism of Pomalidomide can be decreased when combined with Lobeglitazone.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Pomalidomide.Illicit
LopinavirThe metabolism of Pomalidomide can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Loprazolam is combined with Pomalidomide.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Pomalidomide.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Pomalidomide.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Pomalidomide.Approved
LovastatinThe metabolism of Pomalidomide can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Pomalidomide.Approved
LuliconazoleThe serum concentration of Pomalidomide can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Pomalidomide can be decreased when it is combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Pomalidomide.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Pomalidomide.Approved
MebicarThe risk or severity of adverse effects can be increased when Mebicar is combined with Pomalidomide.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Pomalidomide.Approved
MedazepamThe risk or severity of adverse effects can be increased when Medazepam is combined with Pomalidomide.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Pomalidomide.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Pomalidomide.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Pomalidomide.Approved, Investigational
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Pomalidomide.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Pomalidomide.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Pomalidomide.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Pomalidomide.Approved, Investigational
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Pomalidomide.Investigational, Withdrawn
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Pomalidomide.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Pomalidomide.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Pomalidomide.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Pomalidomide.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Pomalidomide.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Pomalidomide.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Pomalidomide.Approved
MethotrimeprazinePomalidomide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Pomalidomide.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Pomalidomide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Pomalidomide.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Pomalidomide.Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Pomalidomide.Experimental
MetyrosinePomalidomide may increase the sedative activities of Metyrosine.Approved
MexiletineThe serum concentration of Pomalidomide can be increased when it is combined with Mexiletine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Pomalidomide.Approved, Illicit
MidostaurinThe serum concentration of Pomalidomide can be increased when it is combined with Midostaurin.Approved
MifepristoneThe serum concentration of Pomalidomide can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.Approved, Investigational
MirtazapinePomalidomide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Pomalidomide can be decreased when it is combined with Mitotane.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Pomalidomide.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Pomalidomide.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Pomalidomide.Approved
NatalizumabThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Natalizumab.Approved, Investigational
NefazodoneThe metabolism of Pomalidomide can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Pomalidomide can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Pomalidomide can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Pomalidomide can be increased when combined with Nevirapine.Approved
NilotinibThe metabolism of Pomalidomide can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Pomalidomide.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Pomalidomide.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Norflurane is combined with Pomalidomide.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Pomalidomide.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Pomalidomide.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Pomalidomide.Approved, Investigational
OlaparibThe metabolism of Pomalidomide can be decreased when combined with Olaparib.Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Pomalidomide.Experimental, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Pomalidomide.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Pomalidomide.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Pomalidomide.Approved, Illicit
OrphenadrinePomalidomide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Pomalidomide.Investigational
OsimertinibThe serum concentration of Pomalidomide can be increased when it is combined with Osimertinib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Pomalidomide.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Pomalidomide.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Oxethazaine is combined with Pomalidomide.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Pomalidomide.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Pomalidomide.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Pomalidomide.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Pomalidomide.Approved, Investigational, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pomalidomide.Approved, Vet Approved
PalbociclibThe serum concentration of Pomalidomide can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Pomalidomide.Approved
ParaldehydePomalidomide may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Pomalidomide can be increased when it is combined with Peginterferon alfa-2b.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Pomalidomide.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Pomalidomide.Approved, Vet Approved
PentobarbitalThe metabolism of Pomalidomide can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Pomalidomide.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Pomalidomide.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Pomalidomide.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Pomalidomide.Experimental
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Pomalidomide.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Pomalidomide.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Phenibut is combined with Pomalidomide.Experimental
PhenobarbitalThe metabolism of Pomalidomide can be increased when combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Pomalidomide.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Pomalidomide.Approved
PhenytoinThe metabolism of Pomalidomide can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pomalidomide.Approved, Investigational
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Pomalidomide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Pomalidomide.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Pomalidomide.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Pomalidomide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Pomalidomide can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexolePomalidomide may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Pomalidomide.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Pomalidomide.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Pomalidomide.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Pomalidomide.Approved
PrimidoneThe metabolism of Pomalidomide can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Pomalidomide.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pomalidomide.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Pomalidomide.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Pomalidomide.Approved
PropanididThe risk or severity of adverse effects can be increased when Propanidid is combined with Pomalidomide.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Pomalidomide.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Pomalidomide.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Pomalidomide.Approved
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Pomalidomide.Experimental
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Pomalidomide.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Proxibarbal is combined with Pomalidomide.Experimental
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Pomalidomide.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Pomalidomide.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Pomalidomide.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Quinisocaine is combined with Pomalidomide.Experimental
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Rabies virus inactivated antigen, A.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Pomalidomide.Approved
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with Pomalidomide.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Pomalidomide.Approved, Investigational
RanolazineThe serum concentration of Pomalidomide can be increased when it is combined with Ranolazine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Pomalidomide.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Pomalidomide.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Pomalidomide.Approved, Investigational
RifabutinThe metabolism of Pomalidomide can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Pomalidomide can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Pomalidomide can be increased when combined with Rifapentine.Approved
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Pomalidomide.Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Pomalidomide.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ritanserin is combined with Pomalidomide.Investigational
RoflumilastRoflumilast may increase the immunosuppressive activities of Pomalidomide.Approved
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Pomalidomide.Vet Approved
RopinirolePomalidomide may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Pomalidomide.Approved
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Pomalidomide.Approved
RotigotinePomalidomide may increase the sedative activities of Rotigotine.Approved
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Pomalidomide.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Pomalidomide.Approved
Salmonella typhi ty21a live antigenThe therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Pomalidomide.Approved
SaquinavirThe metabolism of Pomalidomide can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pomalidomide.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Pomalidomide.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Sepranolone is combined with Pomalidomide.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Pomalidomide.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Pomalidomide.Approved, Vet Approved
SildenafilThe metabolism of Pomalidomide can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Pomalidomide can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Pomalidomide can be increased when it is combined with Simeprevir.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Pomalidomide.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.Approved
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Pomalidomide.Investigational
St. John's WortThe serum concentration of Pomalidomide can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Pomalidomide can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Pomalidomide.Approved, Investigational
SulfisoxazoleThe metabolism of Pomalidomide can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Pomalidomide.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Sultopride is combined with Pomalidomide.Experimental
SuvorexantPomalidomide may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Pomalidomide.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Pomalidomide.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Tasimelteon.Approved
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Pomalidomide.Investigational
TelaprevirThe metabolism of Pomalidomide can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Pomalidomide can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Pomalidomide.Approved
Tenofovir disoproxilThe metabolism of Pomalidomide can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TeriflunomideThe serum concentration of Pomalidomide can be decreased when it is combined with Teriflunomide.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Pomalidomide.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Pomalidomide.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Pomalidomide.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Pomalidomide.Investigational
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Pomalidomide.Investigational
ThalidomidePomalidomide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Pomalidomide can be decreased when combined with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Pomalidomide.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Pomalidomide.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Pomalidomide.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Pomalidomide.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Pomalidomide.Approved
TiaprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Pomalidomide.Approved, Investigational
TiclopidineThe metabolism of Pomalidomide can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Pomalidomide.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Pomalidomide.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Pomalidomide.Approved
TocilizumabThe serum concentration of Pomalidomide can be decreased when it is combined with Tocilizumab.Approved
TofacitinibPomalidomide may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Pomalidomide.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Pomalidomide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Pomalidomide.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Pomalidomide.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Pomalidomide.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Pomalidomide.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Pomalidomide.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Pomalidomide.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Pomalidomide.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trichloroethylene is combined with Pomalidomide.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Pomalidomide.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Trifluperidol is combined with Pomalidomide.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Pomalidomide.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Pomalidomide.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Pomalidomide.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Pomalidomide.Approved, Investigational
VenlafaxineThe metabolism of Pomalidomide can be decreased when combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Veralipride is combined with Pomalidomide.Experimental
VerapamilThe metabolism of Pomalidomide can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Pomalidomide.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Vinyl ether is combined with Pomalidomide.Experimental
VoriconazoleThe metabolism of Pomalidomide can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Pomalidomide.Approved
XenonThe risk or severity of adverse effects can be increased when Xenon is combined with Pomalidomide.Experimental
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Pomalidomide.Vet Approved
Yellow fever vaccineThe therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Pomalidomide.Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Pomalidomide.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Pomalidomide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Pomalidomide can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Pomalidomide.Vet Approved
ZolpidemPomalidomide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Pomalidomide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Pomalidomide.Approved
Zoster vaccineThe therapeutic efficacy of Zoster vaccine can be decreased when used in combination with Pomalidomide.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Pomalidomide.Approved, Investigational
ZucapsaicinThe metabolism of Pomalidomide can be decreased when combined with Zucapsaicin.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Pomalidomide.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Gertz MA: Pomalidomide and myeloma meningitis. Leuk Lymphoma. 2013 Apr;54(4):681-2. doi: 10.3109/10428194.2012.723708. Epub 2013 Jan 2. [PubMed:22917017]
  2. McCurdy AR, Lacy MQ: Pomalidomide and its clinical potential for relapsed or refractory multiple myeloma: an update for the hematologist. Ther Adv Hematol. 2013 Jun;4(3):211-6. doi: 10.1177/2040620713480155. [PubMed:23730498]
  3. Terpos E, Kanellias N, Christoulas D, Kastritis E, Dimopoulos MA: Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma. Onco Targets Ther. 2013 May 10;6:531-8. doi: 10.2147/OTT.S34498. Print 2013. [PubMed:23690693]
External Links
KEGG Drug
D08976
PubChem Compound
134780
PubChem Substance
175427148
ChemSpider
118785
ChEBI
72690
ChEMBL
CHEMBL43452
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Pomalidomide
ATC Codes
L04AX06 — Pomalidomide
AHFS Codes
  • 10:00.00 — Antineoplastic Agents
FDA label
Download (292 KB)
MSDS
Download (479 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0TerminatedTreatmentMultiple Myeloma (MM)1
1Active Not RecruitingOtherMultiple Myeloma (MM)1
1Active Not RecruitingTreatmentHaematological Malignancies / Plasma Cell Myeloma1
1Active Not RecruitingTreatmentImpaired Renal Function / Multiple Myeloma (MM)1
1Active Not RecruitingTreatmentLymphoma, Hodgkins / Multiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL)1
1Active Not RecruitingTreatmentMalignant Lymphomas / Plasma Cell Myeloma1
1Active Not RecruitingTreatmentMultiple Myeloma (MM)4
1Active Not RecruitingTreatmentNeurofibromatosis Type 1 / Recurrent Central Nervous System Neoplasm / Recurrent Childhood Brain Stem Glioma / Recurrent Childhood Visual Pathway Glioma / Refractory Central Nervous System Neoplasm1
1CompletedNot AvailableClinical Pharmacology, Healthy Volunteer Study2
1CompletedNot AvailableHealthy Volunteers2
1CompletedNot AvailableHealthy Volunteers / Pharmacology, Clinical1
1CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL) / Multiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL) / Other B-cell NHL Subtypes, Including WM / T-cell NHL / Waldenstrom's Macroglobulinemia (WM)1
1CompletedTreatmentMultiple Myeloma (MM)1
1CompletedTreatmentMultiple Myeloma (MM) / Multiple Myeloma in Relapse / Refractory Multiple Myeloma1
1CompletedTreatmentSickle Cell Disorders1
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1RecruitingTreatmentBlasts 10-19 Percent of Bone Marrow Nucleated Cells / Blasts 20 Percent or More of Bone Marrow Nucleated Cells / Blasts 5-19 Percent of Peripheral Blood White Cells / Chronic Myelomonocytic Leukemia-2 / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome / Myeloproliferative Neoplasms / Previously Treated Myelodysplastic Syndromes / Untreated Adult Acute Myeloid Leukemia1
1RecruitingTreatmentKaposi s Sarcoma (KS)1
1RecruitingTreatmentMultiple Myeloma (MM)5
1RecruitingTreatmentRelapsed Or Refractory Multiple Myeloma1
1SuspendedTreatmentB-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma / Central Nervous System Lymphoma / Intraocular Lymphoma / Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System / Recurrent Adult Diffuse Large Cell Lymphoma / Retinal Lymphoma1
1SuspendedTreatmentLight Chain Deposition Disease / Primary Systemic Amyloidosis1
1SuspendedTreatmentMultiple Myeloma (MM)1
1SuspendedTreatmentRecurrent Plasma Cell Myeloma1
1TerminatedTreatmentMultiple Myeloma in Relapse1
1TerminatedTreatmentPlasma Cell Myeloma1
1TerminatedTreatmentWaldenstrom's Macroglobulinemia (WM)1
1Unknown StatusTreatmentHereditary Haemorrhagic Telangiectasia (HHT) / Idiopathic Vascular Ectasia1
1, 2Active Not RecruitingTreatmentAL Amyloidosis1
1, 2Active Not RecruitingTreatmentMultiple Myeloma (MM)8
1, 2Active Not RecruitingTreatmentPlasma Cell Myeloma1
1, 2Active Not RecruitingTreatmentRecurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
1, 2Active Not RecruitingTreatmentRefractory Multiple Myeloma1
1, 2CompletedTreatmentChronic Myeloproliferative Disorders / Secondary Myelofibrosis1
1, 2CompletedTreatmentMalignant Neoplasm of Pancreas1
1, 2CompletedTreatmentMultiple Myeloma (MM)2
1, 2CompletedTreatmentPlasma Cell Myeloma1
1, 2RecruitingTreatmentCancer, Advanced1
1, 2RecruitingTreatmentKaposi s Sarcoma (KS)1
1, 2RecruitingTreatmentMultiple Myeloma (MM)5
1, 2RecruitingTreatmentPMF / Post-ET MF / Post-PV MF / Primary Myelofibrosis / Secondary Myelofibrosis / SMF1
1, 2RecruitingTreatmentPlasma Cell Myeloma1
1, 2SuspendedTreatmentMultiple Myeloma in Relapse1
1, 2TerminatedTreatmentCarcinoma, Small Cell1
1, 2WithdrawnTreatmentLarge Cell Lymphoma Arising in KSHV-associated Multicentric Castleman Disease / Primary Effusion Lymphomas1
2Active Not RecruitingTreatmentGraft Versus Host Disease (GVHD)1
2Active Not RecruitingTreatmentMultiple Myeloma (MM)6
2Active Not RecruitingTreatmentMultiple Myeloma (MM) / Relapse After Use of Lenalidomide and Bortezomib1
2Active Not RecruitingTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
2Active Not RecruitingTreatmentMultiple Myeloma in Relapse / Multiple Myeloma, Refractory1
2Active Not RecruitingTreatmentPolycythemia Vera (PV) / Thrombocythemia1
2Active Not RecruitingTreatmentPrimary Amyloidosis of Light Chain Type1
2CompletedTreatmentAgnogenic Myeloid Metaplasia / Myelofibrosis With Myeloid Metaplasia / Myeloid Metaplasia1
2CompletedTreatmentGraft Versus Host Disease (GVHD)1
2CompletedTreatmentMultiple Myeloma (MM)5
2CompletedTreatmentProstate Cancer1
2CompletedTreatmentRecurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
2CompletedTreatmentRelapsed Or Refractory Multiple Myeloma1
2CompletedTreatmentScleroderma, Systemic / Sclerosis, Progressive Systemic1
2Not Yet RecruitingTreatmentMultiple Myeloma (MM)1
2Not Yet RecruitingTreatmentMultiple Myeloma in Relapse1
2Not Yet RecruitingTreatmentRecurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
2RecruitingTreatmentCentral Nervous System Neoplasms / Medulloblastomas1
2RecruitingTreatmentHigh Grade Squamous Intra-epithelial Lesion (HSIL)1
2RecruitingTreatmentLeukemia, Plasma Cell / Plasma Cell Myeloma / Plasmacytoma1
2RecruitingTreatmentMultiple Myeloma (MM)5
2RecruitingTreatmentRelapsed and/or Refractory Multiple Myeloma1
2TerminatedTreatmentSoft Tissue Sarcoma (STS)1
2Unknown StatusTreatmentMyeloproliferative Neoplasms1
2WithdrawnTreatmentMultiple Myeloma (MM)1
2, 3RecruitingTreatmentRelapsed and/or Refractory Multiple Myeloma1
3Active Not RecruitingTreatmentMultiple Myeloma (MM)3
3Active Not RecruitingTreatmentPrimary Myelofibrosis1
3CompletedTreatmentMultiple Myeloma (MM)2
3RecruitingTreatmentMultiple Myeloma (MM)3
3RecruitingTreatmentPlasma Cell Myeloma1
3RecruitingTreatmentRelapse Multiple Myeloma1
3SuspendedTreatmentMultiple Myeloma (MM)1
Not AvailableApproved for MarketingNot AvailableMultiple Myeloma (MM)1
Not AvailableNot Yet RecruitingNot AvailableMultiple Myeloma (MM)1
Not AvailableRecruitingNot AvailableMultiple Myeloma (MM)2

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
CapsuleOral1 mg
CapsuleOral1 mg/1
CapsuleOral2 mg/1
CapsuleOral2 mg
CapsuleOral3 mg/1
CapsuleOral3 mg
CapsuleOral4 mg/1
CapsuleOral4 mg
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6045501No1998-08-282018-08-28Us
US6315720No2000-10-232020-10-23Us
US6561976No1998-08-282018-08-28Us
US6561977No2000-10-232020-10-23Us
US6755784No2000-10-232020-10-23Us
US6908432No1998-08-282018-08-28Us
US8204763No1998-08-282018-08-28Us
US8315886No2000-10-232020-10-23Us
US8626531No2000-10-232020-10-23Us
US8589188No1998-08-282018-08-28Us
US5635517No1999-10-042019-10-04Us
US6316471No1996-08-102016-08-10Us
US6476052No1996-07-242016-07-24Us
US8198262No2004-10-192024-10-19Us
US8673939No2003-05-152023-05-15Us
US8735428No2003-05-152023-05-15Us
US8828427No2011-06-212031-06-21Us
US8158653No1996-08-102016-08-10Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility2.57 mg/mLALOGPS
logP0.02ALOGPS
logP-0.16ChemAxon
logS-2ALOGPS
pKa (Strongest Acidic)11.59ChemAxon
pKa (Strongest Basic)1.56ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area109.57 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity69.03 m3·mol-1ChemAxon
Polarizability25.81 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9653
Blood Brain Barrier+0.8304
Caco-2 permeable-0.6419
P-glycoprotein substrateSubstrate0.5264
P-glycoprotein inhibitor INon-inhibitor0.5983
P-glycoprotein inhibitor IINon-inhibitor0.9147
Renal organic cation transporterNon-inhibitor0.847
CYP450 2C9 substrateNon-substrate0.844
CYP450 2D6 substrateNon-substrate0.8882
CYP450 3A4 substrateSubstrate0.5079
CYP450 1A2 substrateNon-inhibitor0.8863
CYP450 2C9 inhibitorNon-inhibitor0.8428
CYP450 2D6 inhibitorNon-inhibitor0.9002
CYP450 2C19 inhibitorNon-inhibitor0.8513
CYP450 3A4 inhibitorNon-inhibitor0.7289
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8686
Ames testNon AMES toxic0.7979
CarcinogenicityNon-carcinogens0.9081
BiodegradationNot ready biodegradable0.9858
Rat acute toxicity2.5862 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9885
hERG inhibition (predictor II)Non-inhibitor0.7765
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0udi-1590000000-a511655f5e07f3ab2179

Taxonomy

Description
This compound belongs to the class of organic compounds known as phthalimides. These are aromatic heterocyclic compounds containing a 1,3-dioxoisoindoline moiety. They are imide derivatives of phthalic anhydrides.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Isoindoles and derivatives
Sub Class
Isoindolines
Direct Parent
Phthalimides
Alternative Parents
Alpha amino acids and derivatives / Isoindoles / Piperidinediones / Delta lactams / N-substituted carboxylic acid imides / Benzenoids / Vinylogous amides / N-unsubstituted carboxylic acid imides / Dicarboximides / Azacyclic compounds
show 5 more
Substituents
Phthalimide / Alpha-amino acid or derivatives / Isoindole / Piperidinedione / Delta-lactam / Piperidinone / Benzenoid / Piperidine / Carboxylic acid imide, n-substituted / Carboxylic acid imide
show 18 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
dicarboximide, aromatic amine, piperidones, isoindoles (CHEBI:72690)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Metal ion binding
Specific Function
Substrate recognition component of a DCX (DDB1-CUL4-X-box) E3 protein ligase complex that mediates the ubiquitination and subsequent proteasomal degradation of target proteins, such as MEIS2. Norma...
Gene Name
CRBN
Uniprot ID
Q96SW2
Uniprot Name
Protein cereblon
Molecular Weight
50545.375 Da
References
  1. McCurdy AR, Lacy MQ: Pomalidomide and its clinical potential for relapsed or refractory multiple myeloma: an update for the hematologist. Ther Adv Hematol. 2013 Jun;4(3):211-6. doi: 10.1177/2040620713480155. [PubMed:23730498]
  2. Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, Yamaguchi Y, Handa H: Identification of a primary target of thalidomide teratogenicity. Science. 2010 Mar 12;327(5971):1345-50. doi: 10.1126/science.1177319. [PubMed:20223979]
  3. Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J, Karasawa S, Carmel G, Jackson P, Abbasian M, Mahmoudi A, Cathers B, Rychak E, Gaidarova S, Chen R, Schafer PH, Handa H, Daniel TO, Evans JF, Chopra R: Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012 Nov;26(11):2326-35. doi: 10.1038/leu.2012.119. Epub 2012 May 3. [PubMed:22552008]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Tumor necrosis factor receptor binding
Specific Function
Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct ac...
Gene Name
TNF
Uniprot ID
P01375
Uniprot Name
Tumor necrosis factor
Molecular Weight
25644.15 Da
References
  1. Gertz MA: Pomalidomide and myeloma meningitis. Leuk Lymphoma. 2013 Apr;54(4):681-2. doi: 10.3109/10428194.2012.723708. Epub 2013 Jan 2. [PubMed:22917017]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Ferguson GD, Jensen-Pergakes K, Wilkey C, Jhaveri U, Richard N, Verhelle D, De Parseval LM, Corral LG, Xie W, Morris CL, Brady H, Chan K: Immunomodulatory drug CC-4047 is a cell-type and stimulus-selective transcriptional inhibitor of cyclooxygenase 2. J Clin Immunol. 2007 Mar;27(2):210-20. Epub 2007 Feb 17. [PubMed:17308870]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da

Drug created on June 20, 2013 16:45 / Updated on November 22, 2017 12:37